Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q2 2021 vs. Q1 2021
How the institutions holding Damora Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 19 | 27 | +8 |
| Shares | 13.7M | 11.4M | −2.32M (−17.0%) |
| Value | $82.9M | $57.4M | −$25.6M (−30.8%) |
New holders (13)
Institutions that held Damora Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bridgeway Capital Management, LLC | 208,100 | $1.05M | 0.02% |
| Geode Capital Management, LLC | 74,720 | $378.0K | 0.00% |
| Renaissance Technologies LLC | 39,700 | $201.0K | 0.00% |
| Blueshift Asset Management, LLC | 25,238 | $128.0K | 0.01% |
| Vanguard Group Inc | 24,546 | $124.0K | 0.00% |
| Virtu Financial LLC | 12,867 | $65.0K | 0.01% |
| XTX Topco Ltd | 11,018 | $56.0K | 0.02% |
| Tower Research Capital LLC (TRC) | 7,886 | $40.0K | 0.00% |
| UBS Group AG | 7,822 | $40.0K | 0.00% |
| Advisor Group Holdings, Inc. | 400 | $2.00K | 0.00% |
| Citigroup Inc | 242 | $1.00K | 0.00% |
| Morgan Stanley | 111 | $1.00K | 0.00% |
| Salem Investment Counselors Inc | 5 | $0 | 0.00% |
Sold out (5)
Institutions that held Damora Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Sphera Funds Management Ltd. | 448,016 | $2.72M |
| FMR LLC | 133,333 | $810.0K |
| Millennium Management LLC | 82,850 | $503.0K |
| Weiss Multi-Strategy Advisers LLC | 16,154 | $98.0K |
| Goldman Sachs Group Inc | 13,397 | $81.0K |